Essex Bio-Technology Buys Back 71,000 Shares; Outstanding Share Count Trimmed to 566.80 Million

Bulletin Express06-22

Essex Bio-Technology Limited reported the repurchase of 71,000 ordinary shares on 22 June 2026 via on-market transactions on the Hong Kong Stock Exchange.

• Transaction details: Purchase prices ranged between HKD 2.62 and HKD 2.64, resulting in a total outlay of HKD 0.19 million. The volume equates to 0.0125% of the company’s issued share capital (excluding treasury shares) prior to the buyback.

• Treasury shares: All repurchased shares have been retained as treasury stock, lifting the treasury-share balance from 135,000 to 206,000.

• Share capital movement: – Opening balance on 18 June 2026: 566.87 million issued shares (excluding treasury shares). – Post-repurchase balance on 22 June 2026: 566.80 million issued shares (excluding treasury shares). – Total issued shares, including treasury stock, remains unchanged at 567.01 million.

• Repurchase mandate: The share buyback forms part of the mandate granted on 26 May 2026, which authorises Essex Bio-Technology to repurchase up to 56.70 million shares. Cumulative purchases under this mandate now stand at 206,000 shares, representing 0.0363% of the issued share base as of the mandate date.

• Moratorium: In accordance with Hong Kong listing rules, Essex Bio-Technology is restricted from issuing new shares or disposing of treasury shares until 22 July 2026.

The board confirmed that the repurchase complied with all relevant regulatory requirements and that funding for the transaction has been duly settled.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1146950232?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146950232","market":"hk","top_or_hot":-1,"title":"Essex Bio-Technology Buys Back 71,000 Shares; Outstanding Share Count Trimmed to 566.80 Million","media":"Bulletin Express","content":"<p>Essex Bio-Technology Limited reported the repurchase of 71,000 ordinary shares on 22 June 2026 via on-market transactions on the Hong Kong Stock Exchange.</p>\n<p>• Transaction details: Purchase prices ranged between HKD 2.62 and HKD 2.64, resulting in a total outlay of HKD 0.19 million. The volume equates to 0.0125% of the company’s issued share capital (excluding treasury shares) prior to the buyback.</p>\n<p>• Treasury shares: All repurchased shares have been retained as treasury stock, lifting the treasury-share balance from 135,000 to 206,000.</p>\n<p>• Share capital movement:  \n  – Opening balance on 18 June 2026: 566.87 million issued shares (excluding treasury shares).  \n  – Post-repurchase balance on 22 June 2026: 566.80 million issued shares (excluding treasury shares).  \n  – Total issued shares, including treasury stock, remains unchanged at 567.01 million.</p>\n<p>• Repurchase mandate: The share buyback forms part of the mandate granted on 26 May 2026, which authorises Essex Bio-Technology to repurchase up to 56.70 million shares. Cumulative purchases under this mandate now stand at 206,000 shares, representing 0.0363% of the issued share base as of the mandate date.</p>\n<p>• Moratorium: In accordance with Hong Kong listing rules, Essex Bio-Technology is restricted from issuing new shares or disposing of treasury shares until 22 July 2026.</p>\n<p>The board confirmed that the repurchase complied with all relevant regulatory requirements and that funding for the transaction has been duly settled.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Essex Bio-Technology Buys Back 71,000 Shares; Outstanding Share Count Trimmed to 566.80 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEssex Bio-Technology Buys Back 71,000 Shares; Outstanding Share Count Trimmed to 566.80 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-22 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Essex Bio-Technology Limited reported the repurchase of 71,000 ordinary shares on 22 June 2026 via on-market transactions on the Hong Kong Stock Exchange.</p>\n<p>• Transaction details: Purchase prices ranged between HKD 2.62 and HKD 2.64, resulting in a total outlay of HKD 0.19 million. The volume equates to 0.0125% of the company’s issued share capital (excluding treasury shares) prior to the buyback.</p>\n<p>• Treasury shares: All repurchased shares have been retained as treasury stock, lifting the treasury-share balance from 135,000 to 206,000.</p>\n<p>• Share capital movement:  \n  – Opening balance on 18 June 2026: 566.87 million issued shares (excluding treasury shares).  \n  – Post-repurchase balance on 22 June 2026: 566.80 million issued shares (excluding treasury shares).  \n  – Total issued shares, including treasury stock, remains unchanged at 567.01 million.</p>\n<p>• Repurchase mandate: The share buyback forms part of the mandate granted on 26 May 2026, which authorises Essex Bio-Technology to repurchase up to 56.70 million shares. Cumulative purchases under this mandate now stand at 206,000 shares, representing 0.0363% of the issued share base as of the mandate date.</p>\n<p>• Moratorium: In accordance with Hong Kong listing rules, Essex Bio-Technology is restricted from issuing new shares or disposing of treasury shares until 22 July 2026.</p>\n<p>The board confirmed that the repurchase complied with all relevant regulatory requirements and that funding for the transaction has been duly settled.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"","article_id":"1146950232","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146950232","pubTimestamp":1782119074,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Essex Bio-Technology Limited reported the repurchase of 71,000 ordinary shares on 22 June 2026 via on-market transactions on the Hong Kong Stock Exchange. • Transaction details: Purchase prices...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01061":"亿胜生物科技"},"translate_title":"埃塞克斯生物技术公司回购71,000股；流通股数量削减至5.668亿股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1},"content_text":"Essex Bio-Technology Limited reported the repurchase of 71,000 ordinary shares on 22 June 2026 via on-market transactions on the Hong Kong Stock Exchange.\n• Transaction details: Purchase prices ranged between HKD 2.62 and HKD 2.64, resulting in a total outlay of HKD 0.19 million. The volume equates to 0.0125% of the company’s issued share capital (excluding treasury shares) prior to the buyback.\n• Treasury shares: All repurchased shares have been retained as treasury stock, lifting the treasury-share balance from 135,000 to 206,000.\n• Share capital movement:  \n  – Opening balance on 18 June 2026: 566.87 million issued shares (excluding treasury shares).  \n  – Post-repurchase balance on 22 June 2026: 566.80 million issued shares (excluding treasury shares).  \n  – Total issued shares, including treasury stock, remains unchanged at 567.01 million.\n• Repurchase mandate: The share buyback forms part of the mandate granted on 26 May 2026, which authorises Essex Bio-Technology to repurchase up to 56.70 million shares. Cumulative purchases under this mandate now stand at 206,000 shares, representing 0.0363% of the issued share base as of the mandate date.\n• Moratorium: In accordance with Hong Kong listing rules, Essex Bio-Technology is restricted from issuing new shares or disposing of treasury shares until 22 July 2026.\nThe board confirmed that the repurchase complied with all relevant regulatory requirements and that funding for the transaction has been duly settled.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146950232","isCrawlerRequest":true}